NASDAQ: TELATela Bio Inc Stock
$0.72-0.07 (-8.86%)
Updated Aug 12, 2026
TELA Price
$0.72
Fair Value Price
$2.79
Market Cap
$32.32M
52 Week Low
$0.50
52 Week High
$2.00
P/E
-0.94x
P/B
-2.04x
P/S
0.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$79.91M
Earnings
-$41.18M
Gross Margin
67.8%
Operating Margin
-42.48%
Profit Margin
-51.5%
Debt to Equity
-4.77
Operating Cash Flow
-$31M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TELA Overview
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TELA's potential to beat the market
- TELA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
TELA
RankedUnranked of 96
RankedUnranked of 96
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $42.48 | A | |
| $22.03 | A | |
| $13.92 | A |
Be the first to know about important TELA news, forecast changes, insider trades & much more!
TELA News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TELA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TELA ($0.72) is undervalued by 74.16% relative to our estimate of its Fair Value price of $2.79 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TELA ($0.72) is significantly undervalued by 74.16% relative to our estimate of its Fair Value price of $2.79 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TELA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TELA due diligence checks available for Premium users.
Valuation
TELA fair value
Fair Value of TELA stock based on Discounted Cash Flow (DCF)
Price
$0.72
Fair Value
$2.79
Undervalued by
74.16%
TELA ($0.72) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TELA ($0.72) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TELA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TELA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
24.48x
Market
14.4x
TELA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.04x
Industry
3.38x
TELA's financial health
Profit margin
Revenue
$19.3M
Net Income
-$11.3M
Profit Margin
-58.4%
TELA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TELA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$59.7M
Liabilities
$75.6M
Debt to equity
-4.77
TELA's short-term assets ($54.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TELA's long-term liabilities ($57.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TELA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TELA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.4M
Investing
$239.0k
Financing
-$15.0k
TELA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TELA vs Medical Device Stocks
Tela Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.